<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-TNC-08000096</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2008-05-05</date_registration>
      <primary_sponsor>Nanjing University Medical College Affiliated Drum Tower Hospital</primary_sponsor>
      <public_title>Allogenic Bone Marrow Derived Mesenchymal Stem Cells Transplantation For Refractory Systemic Lupus Erythematosus</public_title>
      <acronym />
      <scientific_title>Allogenic Bone Marrow Derived Mesenchymal Stem Cells Transplantation For Refractory Systemic Lupus Erythematosus</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2007-03-01</date_enrolment>
      <type_enrolment />
      <target_size>treating group:50;</target_size>
      <recruitment_status>Completed</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=9429</url>
      <study_type>Observational study</study_type>
      <study_design>Before-After control</study_design>
      <phase>Other</phase>
      <hc_freetext>Refractory Systemic Lupus Erythematosus</hc_freetext>
      <i_freetext>treating group:using allogeneic bone marrow mesenchymal stem cell transplantation;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Sun Lingyun</firstname>
        <middlename />
        <lastname />
        <address>321 Zhongshan Road, Nanjing, China</address>
        <city />
        <country1 />
        <zip>210008</zip>
        <telephone>+86 13705186409</telephone>
        <email>lingyunsun2001@yahoo.com.cn</email>
        <affiliation>Nanjing University Medical College Affiliated Drum Tower Hospital</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Sun Lingyun</firstname>
        <middlename />
        <lastname />
        <address>321 Zhongshan Road, Nanjing, China</address>
        <city />
        <country1 />
        <zip>210008</zip>
        <telephone>+86 13705186409</telephone>
        <email>lingyunsun2001@yahoo.com.cn</email>
        <affiliation />
      </contact>
    </contacts>
    <countries>
      <country2 />
    </countries>
    <criteria>
      <inclusion_criteria>1. all patients fulfilled the American College of Rheumatology (ACR) criteria of SLE, man or woman aged from 15 to 70 years old, SLEDAI&gt;=8;
2. refractory lupus nephritis, 24h urineprotein&gt;=1g;
3. maintain prednisone more than 20 mg/day;
4. ineffective for cyclophosphamide 0.4~0.6/m2 every two weeks for six months, or other immunosuppressive drugs, such as MMF 2 g/day, for three months;
5. patients must sign an informed consent indicating that they are aware of the investigational nature of the study in keeping with the policy of the hosipital.</inclusion_criteria>
      <agemin>15</agemin>
      <agemax>70</agemax>
      <gender>Both</gender>
      <exclusion_criteria>1. abnormal liver function (ALT higer than 3 times the normal value);
2. end-stage renal failure patients;
3. patients who have a severe heart and pulmonary failure, or other important organs damage;
4. undercontrolled infections;
5. pregnant or breast feeding women, male or female who intended to recent pregnancy.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>24-hour proteinuria, urine routine, renal function;liver function;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>blood routine, ES;</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>National Natural Science Foundation, Jiangsu Province Natural Science Foundation,</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2006-04-13</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>